

## REFERENCES

- Annuk M, Zilmer M, Lind L, Linde T and Fellstrom B, (2001):* Oxidative stress and endothelial function in chronic renal failure. *J. Am. Soc. Nephrol.* 12: 2747–2752.
- Aringer M and Graessler J, (2008):* "Understanding deficient elimination of uric acid". *Lancet* 372 (9654): 1929–1930.
- Aronson D and Rayfield EJ, (2002):* How hyperglycemia promotes atherosclerosis: molecular mechanisms. *Cardiovasc. Diabetol.* 1(1):1-7.
- Asipu A, Hayward BE, O'Reilly J and Bonthron DT, (2003):* Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. *Diabetes*, 52: 2426–2432.
- Aymong ED, Curtis MJ and Youssef M, (2002):* Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. *Circulation*, 105: 2981–2985.
- Bagby SP, (2004):* Obesity initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease. *J. Am. Soc. Nephrol.* 15: 2775–2791.
- Baggio B, Budakovic A, Vestra M, Saller a, Baillie JK, Bates AA, Thompson WS, Waring RW, Partridge MF, Schnopp a*

*and Simpson F, (2002):* weight gain and blood pressure elevation. *Hypertension*, 42: 474–480.

*Baillie JK, Thompson WS, Waring RW, Simpson F, Gulliver-Sloan SR and Maxwell DJ, (2007):* "Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude". *Chest*, 131 (5): 1473–1478.

*Baker JF, Krishnan E, Chen L and Schumacher HR, (2005):* Serum uric acid and cardiovascular disease: recent developments and where do they leave us? *Am. J.* 118: 816-826.

*Becker G, (2007):* The CARI guidelines. Kidney stones: uric acid stones. *Nephrology (Carlton)*, 12 Suppl. 1: S21-S25.

*Bedir A, Topbas M, Tanyeri F, Alvur M and Arik N, (2003):* Leptin might be a regulator of serum uric acid concentrations in humans. *Jpn. Heart J.* 44(4): 527-536.

*Bennett-Richards K, Kattenhorn M, Donald A, Oakley G, Varghese Z, Rees L and Deanfield JE, (2002):* Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure? *Circulation*, 105: 1810–1815.

*Bomalaski JS and Clark MA, (2004):* Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. *Curr. Rheumatol. Rep.* 6 (3): 240-247.

**Bos MJ, Koudstaal PJ, Hofman A, Witteman JC and Breteler MM, (2006):** Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study, 37: 1503-1507.

**Boyle JJ, Weissberg PL and Bennett MR, (2003):** Tumor necrosis factor- $\alpha$  promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. *Arterioscler. Thromb. Vasc. Biol.* 23: 1553–1558.

**Brand FN, McGee D, Kannel WB, Stokes J III and Castelli WP, (1985):** Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. *Am. J. Epidemiol.* 121: 11-18.

**Brule D, Sarwar G, Savoie L, Campbell J and Van Zeggelaar, (1988):** *J. Nutr.* 118: 780-786.

**Bruseghin M and Fioretto P, (2002):** Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. *J. Am. Soc. Nephrol.* 13: 2730–2736.

**Burney BO, Kalaitzidis RG and Bakris GL, (2009):** Novel therapies of diabetic nephropathy. *Curr. Opin. Nephrol. Hypertens.* 18 (2):107-111.

**Butler R, Morris AD and Belch JJ, (200):** Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. *Hypertension*, 35:746–751.

**Campion and Glynn, (1987):** treatment of asymptomatic hyperuricemia. *Am. J. Soc. Nephrol.* 17:183–192.

**Campion EW, Glynn RJ and DeLabry LO, (1998):** Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. *Am. J. Med.* 82(3): 421-426.

**Carol N, (1997):** Purine and Pyrimidine Metabolism: Purine Catabolism. *Net.Bio. chem.*, 4 December.

**Chan KH and Segasothy M, (2004):** Gouty arthritis in Australian Aboriginals: more common than previously suspected. *Med. J. Aust.*181:188.

**Chen X, Touyz RM, Park JB and Schiffrin EL, (2001):** Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke prone SHR. *Hypertension*, 38: 606–611.

**Chiarelli F and Gaspari, (2009):** Role of growth factors in diabetic kidney disease. *Horm. Metab. Res.*

**Choi HK, Atkinson K, Karlson EW, Willett W and Curhan G, (2004):** "Purine-rich foods, dairy and protein intake, and the risk of gout in men". *The New England Journal of Medicine*, 350 (11): 1093–1099.

**Choi JW, Ford ES, Gao X and Choi HK, (2008):** Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. *Arthritis Rheum.* 59: 109-116.

**Clausen T, Slott M, Solvoll K, Drevon CA, Vollset SE and Henriksen T, (2001):** High intake of energy, sucrose, and polyunsaturated fatty acids is associated with increased risk of preeclampsia. *Am.J. Obstet. Gynecol.*, 185:451–458.

**Cirillo P, Sato W, Reungjui S, Heinig M, Gersch M, Sautin Y, Nakagawa T and Johnson RJ, (2006):** Uric Acid, the metabolic syndrome, and renal disease. *J. Am. Soc. Nephrol.* 17[Suppl 3]: S165–S168.

**Cohn GS, Kittleson MM and Blumenthal RS, (2005):** Toward an improved diagnosis of the metabolic syndrome other clues to the presence of insulin resistance. *Am. J. Hypertens.* 18: 1099–1103.

**Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F and Burnier M, (2004):** Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. *BMC Public Health.* 4(1):9-15.

**Cooper ME, (1998):** Pathogenesis, prevention, and treatment of diabetic nephropathy. *Lancet*, 352 (9123):213-219.

**Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H and Tuck ML, (2008):** Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. *J. Hypertens.* 26:269–275.

**Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF and Kullo IJ, (2007):** Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. *Am. J. Hypertens.* 20: 83–89.

**Culleton BF, Larson MG, Kannel WB and Levy D, (1999):** Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. *An. Intern. Med.;* 131(1):7-13.

**Dalbeth N and Merriman T, (2009):** New therapeutic targets for hyperuricaemia and gout. *Rheumatology (Oxford).* 48(3):222-6.

**Dalla Vestra M, Mussap M, Gallina P, Brueghin M, Cernigoj AM, Saller A, Plebani M and Fioretto P, (2005):** Acute phase markers of inflammation and glomerular structure in patients with type 2 diabetes. *J. Am. Soc. Nephrol.* 16 [Suppl 1]: S78–S82.

**Daudon M, Dore JC, Jungers P and Lacour B, (2004):** Changes in stone composition according to age and gender of

patients: A multivariate epidemiological approach. *Urol. Res.* 32: 241–247.

***Davis N, (1987):*** The cardiovascular and renal relations and manifestations of gout. 29:261-269.

***De Boer IH and Steffer MW, (2007):*** Glomerular Filtration rate and albuminuria. *J. Am. Soc. Nephrol.* 18: 1036-1037.

***De Bont JM and Pieters R, (2004):*** Management of hyperuricemia with rasburicase review. *Nucleosides Nucleotides Nucleic Acids*, 23(8-9):1431-1440.

***Dehghan A, van Hoek M, Sijbrands EJ, Hofman a and Witteman JC, (2008):*** "High serum uric acid as a novel risk factor for type 2 diabetes". *Diabetes Care* 31 (2): 361–362. Detection of renal failure in a cohort of screened subjects.

***Dierk H, Endemann, Ernestol and Schiffrin, (2004):*** Endothelial Dysfunction. *Am. J. Soc. Nephrol.* 15:1983–1992.

***Doehner W, Schoene N and Rauchaus M, (2002):*** Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. *Circulation*, 105: 2619–2624.

**Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA and Griffin MD, (2007):** Resident dendritic cells are the predominant TNFsecreting cell in early renal ischemia-reperfusion injury. *Kidney Int.* 71: 619–628.

**Doring A, Gieger C and Mehta D, (2008):** SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. *Nat. Genet.;* 40:430-436.

**Drexler H, (1998):** Factors involved in the maintenance of endothelial function. *Am. J. Cardiol.* 82:3S–4S.

**Edmond O’Riordan, Jun Chen, Sergey V, Brodsky, Iva Smirnova, Hong Li and Michael S, (2005):** Endothelial cell dysfunction, the syndrome in making. *Kidney International*, Vol.67, pp.1654-1658.

**Ekong EB, Jaar BG and WeaverVM, (2006):** Lead-related nephrotoxicity: a review of the epidemiologic evidence. *Kidney Int.* 70: 2074–2084.

**Elizabeth T, Rosolowsky, Linda H, Monika A and Amanda L, (2008):** HbA1c and uric acid as a part of MS. doi:10.2215/CJN.04271007.

**Emeka A, William W, Amos A, (2006):** serum uric acid correlates with the progression of nephropathy in patients with diabetes mellitus. *Pak. J. Med. Sci.* Vol., 22 no. 4.

**Enomoto A, Kimura H, Chairoungdua a, Shigeta Y, Jutabha P and Cha SH, (2002):** Molecular identification of a renal

urate anion exchanger that regulates blood urate levels. *Nature*; 417(6887):447-452.

***Ephraim R, Owiredu E, Laing N, Amidu B, Eghan Jr and Ahenkorah, (2008):*** Anaemia as a risk factor for cardiovascular disease in patients with chronic kidney disease. *J. Med. Sci.*, 8: 707-714.

***Epstein M, (1996):*** Aging and the kidney. *J. Am. Soc. Nephrol.* 7:1106-1122.

***Eraly S, Vallon V and Rieg T, (2008):*** Multiple organic anion transporters contribute to net renal excretion of uric acid. *Physiol. Genomics*; 33: 180–192.

***Fang J and Alderman MH, (2000):*** Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. *National Health and Nutrition Examination Survey. JAMA*, 283:2404-2410.

***Farquharson CA, Butler R and Hill A, (2002):*** Allopurinol improves endothelial dysfunction in chronic heart failure. *Circulation*, 106: 221–226.

***Feig DI and Johnson RJ, (2003):*** Hyperuricemia in childhood primary hypertension. *Hypertension*, 42: 247-452.

***Feig DI, Nakagawa T and Karumanchi SA, (2004):*** Uric acid, nephron number, and the pathogenesis of essential hypertension. *Kidney Int.* 66: 281-287.

**Ficoiello LH, Perkins BH, Silva KH and Cupples AS, (2007):**  
Determination of progression from microalbuminuria to proteinuria in DM. Clin. J. Am. Soc. Nephrol. 2: 461-469.

**Ford ES, Li C, Cook S and Choi HK, (2007):** Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation, 115: 2526-2532.

**Forman JP, Choi H and Curhan GC, (2007):** Plasma uric acid level and risk for incident hypertension among men. J. Am. Soc. Nephrol. 18: 287-292.

**Freedman DS, Williamson DF, Gunter EW and Byers T, (1995):**  
Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. Am. J. Epidemiology, 141: 637-644.

**Friedman, Meyer; Byers, and Sanford O, (1948):** Observations concerning the causes of the excess excretion of uric acid in the Dalmatian dog". The Journal of Biological Chemistry, 175 (2): 727-735.

**Gersch C, Pali SP, Kim KM, Angerhofer A, Johnson RJ and Henderson GN, (2008):** Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 27: 967-978.

**Gertler MM, Garn SM and Levine SA, (1951):** Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann. Intern. Med. 34: 142131.

**Gohnson RJ, Tittle S, Cade JR, Rideout BA and Oliver WJ, (2008):** Uric acid, evolution and primitive cultures. *Semin Nephrol.* 25: 3-8.

**Gross LS, Li L, Ford ES and Liu S, (2004):** Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. *Am. J. Clin. Nutr.* 79: 774–779.

**Harris MD, Siegel LB and Alloway JA, (1998):** Gout and hyperuricemia. *Am. Fam. Physician;* 59(4): 925-934.

**Havel PJ, (2005):** Dietary fructose implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. *Nutr. Rev.*63: 133–157.

**Hayden MR, (2004):** Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. *Medical Hypotheses and Research,* 1(2–3): 171-185.

**Hayden MR and Tyagi SC, (2002):** Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. *Atheroscleropathy, Cardiovasc. Diabetol.* 1(1):3-9.

**Hayden MR and Tyagi SC, (2004):** Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. *Nutr. J.* 3(1):4-7.

**Hazard and Lisa C, (2004):** Sodium and Potassium Secretion by Iguana Salt Glands. University of California Press. pp. 84–85.

**Heinig M and Johnson RJ, (2006):** Role of uric acid in hypertension, renal disease, and metabolic syndrome. *Cleve. Clin. J. Med.* 73: 1059–1064.

**Heitzer T, Schlinzig T, Krohn K, Meinertz T and Munzel T, (2001):** Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation*, 104: 2673–2678.

**Henry RJ, (1974):** Principles and techniques. *Clin. Chem.* 2nd Ed. Harper and Row, pp.543-548.

**Hofman A and Witteman JC, (2008):** High serum uric acid as a novel risk factor for type 2 diabetes. *Diabetes Care* 31:361-362.

**Hossain P, Kavar B and El Nahas M. (2007):** Obesity and diabetes in the developing world. A growing challenge, *N. Engl. J. Med.* 356: 213–215.

**Hunt SC, Stephenson SH, Hopkins PN and Williams RR, (1991):** Predictors of an increased risk of future hypertension in Utah: a screening analysis. *Hypertension*, 17:969-976. *Hypertens. Res.* 24:691-697.

***Inzucchi SE and Sherwin RS, (2007):*** Diabetes Mellitus. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier: chap 248.

***Isam H Mahmood, (2007):*** Serum Uric Acid Concentration in patients with Type 2 Diabetes Mellitus during Diet or Glibenclamide Therapy. *Pak J. Med. Sci.* Vol. 23 No. 3:361-365.

***Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K and Takishita S, (2001):*** Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. *Am. J. Kidney Dis.* 44: 642-650.

***Isek K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Jacobsen P, Rossing K and Parving HH, (2004):*** Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. *Curr. Opin. Nephrol. Hypertens.* 13(3): 319-324.

***Iwasaki S, Homma T, Matsuda Y and Kon V, (1995):*** Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. *J. Biol. Chem.* 270: 6997-7003.

***Jacobsen P, Rossing K and Parving HH, (2004):*** Single versus dual blockade of the renin angiotensin system (angiotensin converting enzyme inhibitors and or

*angiotensin II receptor blockers) in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens, 13:319-324.*

***Jan Galle, Thomas Quaschnig, Stefan Seibol, and Christoph Wanner, (2003):*** Endothelial dysfunction and inflammation: What is the link? Vol. 63, Supplement, 84 pp. S45–S49.

***Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J and Mazzali M, (2003):*** Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension, 41(6):1183-1190.*

***Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W and Roncal C, (2005):*** Essential Hypertension, Progressive Renal Disease, and Uric Acid: A pathogenetic Link? *J. Am. Soc. Nephrol. 16: 1909-1916.*

***Juan F, Navarro-Gonzalez and Carmen Mora-Fernandez, (2008):*** The Role of Inflammatory Cytokines in Diabetic Nephropathy. *J. Am. Soc. Nephrol. 19: 433–442.*

***Kanabrocki EL, Third JL and Ryan MD, (2000):*** Circadian relationship of serum uric acid and nitric oxide. *J. AMA. 283: 2240–2241.*

***Kang DH, Finch J, Nakagawa T, Karumanchi SA, Kanellis J, Granger J and Johnson RJ, (2004):*** Uric acid,

endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. *Hypertens.* 22: 229–235.

***Kang DH, Park SK, Lee IK and Johnson RJ, (2005):*** Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. *J. Am. Soc. Nephrol.* 16: 3553-3562.

***Kawasaki T, Akanuma H and Yamanouchi T, (2002):*** Increased fructose concentrations in blood and urine in patients with diabetes. *Diabetes Care,* 25: 353–357.

***Keller G, Zimmer G, Mall G, Ritz E and Amann K., (2003):*** Nephron number in patients with primary hypertension. *N. Engl. J. Med.* 348:101-8. *Kidney Dis.* 47: 51-59.

***Kim SY, Guevara JP and Kim KM, (2009):*** Hyperuricemia and risk of stroke: a systematic review and meta-analysis , 61(7): 885-92.

***Kimmelstiel P and Wilson C, (1936):*** Benign and malignant hypertension and nephrosclerosis. A clinical and pathological study. *Am. J. Pathol.* 12: 45-48.

***King H, Auburt RE and Herman WH,(1998):*** Global burden of Diabetes 1995- 2025. Prevalence, numerical estimates and projections: *Diabetes Care,* 21: 1414-1431.

**Kolz M., Johnson T and Kim KM, (2009):** "Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations.

**Kostadaras A, (2009):** Risk Factors for Diabetic Nephropathy. Astoria Hypertension Clinic.

**Krolewski AS, Laffel LM, Krolewski M and Warram JH, (2005):** HbA1c and the risk of Microalbuminuria in DM. N. Engl. J. Med. 332: 1251-1255.

**Lee JE, Kim YG, Choi YH, Kim D and Oh HY, (2006):** Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension, 47: 962-967.

**Levin A, Hemmelgarn B and Culeton B, (2008) :**"Guidelines for the management of chronic kidney disease". CMA, J. 179 (11): 1154–1162.

**Libby P, (2002):** Inflammation in atherosclerosis. Nature 420: 868–874.

**Lilian Anekwe, (2010):** Diabetes work to soar under HbA1c switch.

**Lloyd A and Burchett I, (1998):** Broadsheet number 43: The role of the laboratory in the investigation and management of hyperuricemia. Patholog. 30(2): 141-146.

**Liu S, Choi HK, Ford E, Song Y, Klevak A, Buring JE and Manson JE, (2006):** A prospective study of dairy

intake and the risk of type 2 diabetes in women. *Diabetes Care*, 29: 1579–1584.

**Luo YC, Do JS and Liu CC, (2006):** "An amperometric uric acid biosensor based on modified Ir-C electrode". *Biosensors & Bioelectronics* 22.

**Lu'scher TF and Barton M, (1997):** Biology of the endothelium. *Clin. Cardiol.* 20(suppl II): II-3-II-10.

**Madero M, Sarnak M and Wang X, (2009):** Uric acid and long-term outcomes in CKD. *Am. J. Kidney Dis.*; 53: 796–803.

**Maeaka and Fishbane, (1998):** factors affected urate excretion. *J. Nutr.* 880 - 886.

**Marino E and Cardier JE, (2003):** Differential effects of IL-18 on endothelial cell apoptosis mediated by TNF-alpha and Fas (CD59). *Cytokine* 22: 142–148.

**Mary Ann, Naim M, Beverley A, Orson W and Khashayar S, (2006):** Urine Composition in Type 2 Diabetes: Predisposition to Uric Acid Nephrolithiasis *J. Am. Soc. Nephrol.* 17: 1422–1428.

**Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang D-H, Gordon KL, Lan HY, Kivlighn S and Johnson RJ, (2001):** Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension*, 38: 1101–1106.

**Mazzali M, Kanellis J, Han L, Feng L, Chen Q, Kang DH, Watanabe S, Nakagawa T, Lan HY and Johnson RJ, (2002):** Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure-independent mechanism. *Am. J. Physiol. Renal Physiol.* 282: F991–F997.

**Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson JA, Hughes J, Kivlighn SD, Lan HY and Johnson RJ, (2001):** Hyperuricemia exacerbates chronic cyclosporine nephropathy. *Transplantation*, 71: 900–905.

**Mercuro G, Vitale C and Cerquetani E, (2004):** Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. *Am. J. Cardiol.* 94: 932-935.

**Michel D, Olivier T, Pierre C, Bernard L and Paul Jungers, (2006):** Type 2 Diabetes Increases the Risk for Uric Acid Stones. *J. Am. Soc. Nephrol.* 17: 2026–2033.

**Moreland S, McMullen DM, Delaney CL, Lee VG and Hunt JT, (1992):** Venous smooth muscle contains vasoconstrictor ETB-like receptors. *Biochem. Biophys. Res. Commun.*, 184: 100–106.

**Msuo K, Kawaguchi H, Mikami H, Ogihara T and Tuck ML, (2004):** Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. *Hypertension*, 42: 474-80.

***Nakagawa T, Hu H and Zharikov S, (2006):*** "A causal role for uric acid in fructose-induced metabolic syndrome". *American Journal of Physiology. Renal Physiology* 290 (3): F625–631.

***Nakagawa T, Tuttle KR, Short RA and Johnson RJ, (2007):*** Fructose-induced hyperuricemia as a casual mechanism for the epidemic of the metabolic syndrome. *Nat. Clin. Pract. Nephrol.* 1: 80-86.

***Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K and Tatara K, (2003):*** Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. *Eur. J. Epidemiol.* 18: 523–530.

***Nan H, Dong Y, Gao W, Tuomilehto J and Qiao Q, (2006):*** Diabetes associated with a low serum uric acid level in a general Chinese population. *Diabetes Res. Clin. Pract.*

***National Kidney Foundation, (2008):*** Diabetes and Kidney Disease.

***Navarro JF, Milena FJ, Mora C, Leon C and Garcí'a J, (2006):*** Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration, *Am. J. Nephrol.* 26: 562–570.

**Nickeleit V and Mihatsch MJ, (1997):** Uric acid nephropathy and end stage renal disease: Review of a non-disease. *Nephrol. Dial. Transpl.* 12: 1832–1838.

**NIDDK, (2008):** National Institute of Diabetes and Digestive and Kidney Diseases.

**Nieto FJ, Iribarren C, Gross MD, Comstock GW and Cutler RG, (2000):** Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? *Atherosclerosis*, 148: 131-139.

**Niskanen L, Laaksonen DE and Lindstrom J, (2006):** Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. *Diabetes Care*, 29: 709-711. *Hypertension*; 17: 969-976.

**Nonkivell BJ, (2001):** Creatinine clearance and assessment of renal function. *Aust. Prescr.* 24: 15-17.

**Nyhan WL, (2005):** "Lesch-Nyhan Disease". *Journal of the History of the Neurosciences*; 14 (1): 1–10.

**Nyyssonen K, Porkkala-Sarataho E, Kaikkonen J and Salonen JT, (1997):** Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. *Atherosclerosis*, 130(1–2): 223-233.

- Ogura T, Matsuura K, Matsumoto Y, Mimura Y, Kishida M, Otsuka F and Tobe K, (2004):** Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. *Metabolism*, 53(4): 448-453.
- Olexa P, Olexova M, Gonsorcik J, Tkac I, Kisel'ova J and Olejnikova M, (2002):** Uric acid a marker for systemic inflammatory response in patients with congestive heart failure? *Wien Klin. Wochenschr*, 114(5–6): 211-215.
- Ortiz A, Bustos C, Alonso J, Alcazar R, Lopez-Armada MJ, Plaza JJ, Gonza'lez E and Egido J, (1995):** Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. *Adv. Nephrol. Necker Hosp.* 24: 53–77.
- Pak CY, (2008):** "Medical stone management: 35 years of advances". *The Journal of Urology*, 180 (3): 813–819.
- Pak CY, Sakhaee K, Peterson RD, Poindexter JR and Frawley WH, (2001):** Biochemical profile of idiopathic uric acid nephrolithiasis. *Kidney Int.* 60: 757–761.
- Pan WH, Flegal KM and Chang HY, (2004):** Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. *Am. J. Clin. Nutr.* 79: 31-39.
- Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S and Arner P, (2001):** The effect of irbesartan on the

development of diabetic nephropathy in patients with type 2 diabetes. *N. Engl. J. Med.* 345: 870–878.

***Parving H, Mauer M and Ritz E, (2007):*** Diabetic Nephropathy. In: Brenner BM. *Brenner and Rector's the Kidney*. 8th ed. Philadelphia, Pa: Saunders Elsevier: chap 36.

***Pepys MB, Dash AC and Ashley MJ, (1977):*** *Clin. Exp. Immunol.* 30: 32-37.

***Perez-Ruiz F, Gomez-Ullate P and Amenabar JJ, (1999):*** Long-term efficacy of hyperuricaemia treatment in renal transplant patients. *Nephrol. Dial. Transplant.* 18: 603-606.

***Perkins BA, Ficociello LH, Silva KH and Warm JH, (2003):*** Regression of Microalbuminuria in Type 1 Diabetes. *N. Engl. J. Med.* 348: 2285-2293.

***Perkins BA, Ficociello LH, Silva KH and Warm JH, (2007):*** Microalbuminuria and risk of early renal function loss in DM. *J. Am. Soc. Nephrol.* 18:1353-1361.

***Proctor P, (1970):*** "Similar functions of uric acid and ascorbate in man?" *Nature* 228 (5274): 868-875.

***Quinones Galvan A, Natali A and Baldi S, (1995):*** Effect of insulin on uric acid excretion in humans. *Am. J. Physiol.* 268: E1-E5.

***Remuzzi G and Benigni A, (1993):*** Endothelins in the control of cardiovascular and renal function. *Lancet* 342: 589–593.

**Reungjui S, Roncal CA, MuW, Srinivas TR, Sirivongs D, Johnson RJ and Nakagawa T, (2007):** Thiazide diuretics exacerbate fructose-induced metabolic syndrome. *J. Am. Soc. Nephrol.* 18: 2724–2731.

**Ridker PM, Wilson PW and Grundy SM, (2004):** Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? *Circulation* 109(23): 2818-2825.

**Roberts JM, Bodnar LM and Lain KY, (2005):** Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. *Hypertension*, 46: 1263-1269.

**Rosolowsky ET, Ficociello LH, Maselli NJ, Niewczas MA, Binns AL, Roshan B, Warram JH and Krolewski AS, (2008):** High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. *Clin. J. Am. Soc. Nephrol.* 3:706–713.

**Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M and Johnson RJ (2008):** Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. *Am. J. Physiol.* 294: F710–F718.

**Sautin YY, Nakagawa T, Zharikov S and Johnson RJ, (2007):** Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. *Am. J. Physiol. Cell Physiol.* 293: C584–C596.

**Schettler G and Nussel E, (1975):** *Arb. Med. Prov., Med.,* 10, 25.

**Schiffrin EL and Touyz RM, (2003):** *Multiple actions of angiotensin II in hypertension: Benefits of AT1 receptor blockade. J. Am. Coll. Cardiol.* 42: 911–913.

**Schumacher HR Jr, Becker M and Lloyd E, (2009):** Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. *Rheumatology (Oxford).*48(2):188-194.

**Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC and Laragh JH, (1999):** On the renal basis for essential hypertension: Nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. *J. Hypertens.* 6: 763–777.

**Shankar A, Klein R, Klein BE and Nieto FJ, (2006):** *The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J. Hum. Hypertens.* 20: 937-945.

**Shapiro A, Mu W, Roncal CA, Cheng KY, Johnson RJ and Scarpace, (2008):** Fructose-induced leptin resistance exacerbates weight gain in response to subsequent

high fat feeding. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 295: R1370–R1375.

***Shlipak M, (2009):*** Diabetic nephropathy. *Clin Evid* (Online).

***Siu YP, Leung KT, Tong MK and Kwan TH, (2006):*** Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. *Am. J. Kidney Dis.* 47: 51-59.

***Sowers JR, (2002):*** Hypertension, angiotensin II, and oxidative stress. *N. Engl. J. Med.* 346: 1999–2001.

***Sritara P, Kitiyakara C, Stichantrakul W, Krittaphol V and Lolekha P,(2005):*** Risk factors for development of decreased kidney function in a Southeast Asian population: A twelve year co-heart study. *J. Am. Soc. Nephrol.* 16: 791-799.

***Stanhope KL and Havel PJ, (2008):*** Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. *Curr. Opin. Lipidol* 19:16–24.

***Stevens T, Rosenberg R and AIRD W, (2001):*** NHBLI workshop report: Endothelial cell phenotypes in heart, lung and blood diseases. *Am. J. Physiol. Cell Physiol.* 281: C1422-C1433.

***Stumvoll M, Goldstein BJ and van Haeften TW, (2005):*** Type 2diabetes Principles of pathogenesis and therapy. Lancet, 365: 1333–1346.

***Sui X, Church TS, Meriwether RA, Lobelo F and Blair SN, (2008):*** Uric acid and the development of metabolic syndrome in women and men. Metabolism, 57: 845–852.

***Syamala S, Li J and Shankar A, (2007):*** Association between serum uric acid and prehypertension among US adults. J. Hypertens. 25: 1583-1595.

***Takishita S, (2001):*** Significance of hyperuricemia on the early Treatment of chronic gout in patients with renal function impairment. An open, randomized actively controlled study. J. Clin. Rheumatol. 5: 49–55.

***Talaat KM and El-Sheikh AR, (2007):*** The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am. J. Nephrol. 27: 435-440.

***Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S and Toyoshima H, (2003):*** The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int. J. Obes. Relat. Metab. Disord. 27(4): 443-449.

**Tausche AK, Unger S and Richter K, (2006):** "Hyperurikämie und Gicht [Hyperuricemia and gout: diagnosis and therapy]".

**Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, Ganten D, Haller H, Dietz R and Luft FC, (2002):** Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. *BMC, Cardiovasc. Disord* 2: 3–14.

**Tietz NW, (1994):** Textbook of Clinical Chemistry pp 58-69.

**Tomoki Kosugi, Takahiro Nakayama, Marcelo Heinig, Li Zhang, Yukio Yuzawa, Laura Gabriela Sanchez-Lozada, Carlos Roncal, Richard J. Johnson and Takahiko Nakagawa, (2009):** Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. *Am. J. Physiol. Renal Physiol.* 297: F481–F488.

**Tonelli M, Wiebe N and Culleton B, (2006):** "Chronic kidney disease and mortality risk: a systematic review". *J. Am. Soc. Nephrol.* 17 (7): 2034–2047.

**Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ and Schiffrin EL, (2002):** Expression of a functionally active gp91phox containing neutrophil-type NAD (P) H oxidase in smooth muscle cells from human resistance arteries: Regulation by angiotensin II. *Circ. Res.* 90: 1205–1213.

**Tseng C-H, (2005):** Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. *Kidney Int.* 68: 796–801.

**Uday M, Sergey Zharikov, Jennifer L, Takahiko Nakagawa, Carlos Roncal, Wei Mu, Karina Krotova, Edward R, Sharma Prabhakar, and Richard J, (2005):** Hyperuricemia induces endothelial dysfunction, *Kidney International*, Vol.67, pp.1739n1742.

**Ueno M, Tomita Y, Tsuchihashi T, Takishita S and Fujishima M, (1988):** Clinical alterations in normotensive offspring with parental hypertension. *J. Hypertens. Supp.* 6: S50-S51.

**Vaziri ND, Freel RK and Hatch M, (1995):** Effect of chronic experimental renal insufficiency on urate metabolism. *J. Am. Soc. Nephrol.* 6: 1313–1317.

**Verma S and Anderson TJ, (2002):** Fundamentals of endothelial function for the clinical cardiologist. *Circulation*, 105: 546–549.

**Villegas R, Xiang Y and CAI Q, (2010):** Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. *Metab. Syndr. Relat. Disord.*

**Virdis A, Ghiadoni L, Cardinal H, Favilla S, Duranti P, Birindelli R, Magagna A, Bernini G, Salvetti G, Taddei S and Salvetti A, (2001):** Mechanisms responsible for endothelial dysfunction induced by fasting

hyperhomocystinemia in normotensive subjects and patients with essential hypertension. *J. Am. Coll. Cardiol.* 38: 1106–1115.

***Vitart V, Rudan I and Hayward C, (2008):*** "SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout". *Nature Genetics*, 40 (4): 437–42.

***Watanabe S, Kang DH and Feng L, (2002):*** Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. *Hypertension*, 40: 355-360.

***Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL and den Heijer M, (2008) :*** Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Comment in: *Kidney Int.* Jun;73(11): 1325-1326.

***Xiao S, Wagner L, Schmidt RJ and Baylis C, (2001):*** Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. *Kidney Int.* 59: 1466–1472.

***Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T, (1988):*** A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 332: 411–415.

**Young W, Mahboubi K, Haider A, Li I and Ferreri NR, (2000):** Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. *Circ. Res.* 86: 906–914.

**Zelmanovitz T, Gerchman F and Balthazar AP, (2009):** Diabetic nephropathy. *Diabetol. Metab. Syndr.* 21; 1(1):10-16.

**Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, Hofmann SM, Vlassara H and Shi Y, (2003):** Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. *Circulation*, 108: 472–478.

**Zoccali C, Mallamaci F, Tripepi G, Cutrupi S and Pizzini P, (2006):** Low triiodothyronine and survival in end-stage renal disease. *Kidney Int.* 70: 523–528.